Treatment of heparin-induced thrombocytopenia with fondaparinux.
Anticoagulation of patients with heparin-induced thrombocytopenia (HIT) may be limited by cross-reaction of HIT antibodies with danaparoid and generation of antibodies during therapy with lepirudin. We used fondaparinux to treat 6 patients with a history of HIT with thromboembolism and 2 patients with thrombocytopenia during low-molecular-weight heparin administration.
Harenberg
Job
J
Jörg
Ingrid
I
Fenyvesi
Tivadar
T
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D000077425:Fondaparinux; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects*; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy*; D016896:Treatment Outcome
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D000077425:Fondaparinux